The earnings call displayed a mixed sentiment. While there were strong performances and strategic moves in the Just - Evotec Biologics segment, challenges were apparent in the Discovery & Preclinical Development segment, with revenue declines and a negative group EBITDA. The strategic sale and cost reductions are positive markers, but the overall financial performance and market conditions introduce caution.

Company Guidance

During the Evotec SE Half Year Report 2025 Conference Call, the company provided guidance reflecting a mixed performance across their business segments. The Discovery & Preclinical Development (D&PD) segment saw an 11% revenue decline, attributed mainly to a temporary effect in their collaboration with BMS and a softer early drug discovery market. However, Just - Evotec Biologics (JEB) reported a 16% revenue increase year-over-year, driven by strong demand and growth with non-Sandoz and Department of Defense (DOD) customers. The company emphasized their strategic shift towards a more capital-efficient model by planning the sale of their Toulouse site to Sandoz, aiming to enhance their revenue mix and improve profit margins. Despite a 5% decrease in group revenues to EUR 371 million in H1 2025, Evotec maintains their full-year guidance, anticipating a recovery in venture capital funding and an improved business mix in the latter half of the year.

Just - Evotec Biologics Revenue Growth

Just - Evotec Biologics reported a 16% revenue growth year-over-year, with significant contributions from three large pharma companies and a broadening customer base.

Cost Reduction Achievements

The company has achieved EUR 60 million in cost reductions for 2025, including a 35% reduction in R&D spending and a 50% decrease in CapEx compared to 2024.

Strategic Sale of Toulouse Site

Evotec announced the planned sale of its Toulouse site to Sandoz for around USD 300 million, aligning with its strategy to pivot towards a CapEx-lighter business model.

Molecular Patient Database Expansion

Evotec expanded its molecular patient database to include data from over 27,000 patients, enhancing its precision medicine capabilities and expanding its therapeutic focus.

Positive Outlook on Just - Evotec Biologics

The company remains bullish about the prospects for Just - Evotec Biologics, with plans to strengthen its intellectual property and leadership position in continuous manufacturing.

Evotec AG (EVO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EVO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.05 / -	-0.118	―	―	―
Aug 13, 2025	2025 (Q2)	-0.07 / -0.14	-0.298	51.68% (+0.15)
May 06, 2025	2025 (Q1)	- / -	-0.066	―
Apr 17, 2025	2024 (Q4)	-0.04 / -0.10	-0.066	-54.55% (-0.04)
Nov 06, 2024	2024 (Q3)	-0.06 / -0.12	-0.118	0.00% (0.00)
Aug 14, 2024	2024 (Q2)	-0.04 / -0.30	-0.043	-593.02% (-0.26)
May 22, 2024	2024 (Q1)	- / -	-0.017	―
Apr 24, 2024	2023 (Q4)	-0.03 / -0.07	-0.017	-288.24% (-0.05)
Nov 08, 2023	2023 (Q3)	-0.03 / -0.12	-0.14	15.71% (+0.02)
Aug 29, 2023	2023 (Q2)	-0.06 / -0.04	-0.08	46.25% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EVO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$3.81	$3.81	0.00%
May 06, 2025	$4.17	$4.05	-2.88%
Apr 17, 2025	$3.27	$3.60	+10.09%
Nov 06, 2024	$4.58	$3.86	-15.72%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Evotec AG (EVO) report earnings?

Evotec AG (EVO) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Evotec AG (EVO) earnings time?

Evotec AG (EVO) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EVO EPS forecast?

EVO EPS forecast for the fiscal quarter 2025 (Q3) is -0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing